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Progression of renal damage in chronic rejection. A significant ciated with glomerular and tubulointerstitial changes.
complication in renal transplantation is the progressive decline The arterial intimal fibrosis (also called transplant arte-
of allograft function, commonly called chronic rejection. This
riopathy) may affect the small preglomerular arteriolescomplication has been regarded as a result of continuous immu-
as well as interlobular arteries and even the main renalnological activity against the allograft. However, the role of
nonimmunological factors has become increasingly apparent artery. Initially, there are proliferative changes of the
in triggering or exacerbating immunological mechanisms. Al- intimal and smooth muscle cells, followed by progressive
though the role of immunological factors is predominant, the
vascular sclerosis and obliteration caused by extracellu-correction of nonimmunological factors may contribute in im-
lar matrix deposition [1]. The glomeruli may show anproving the probability of long-term graft function. However,
immunosuppressive therapy remains the cornerstone for re- increase in mesangial cell and matrix, thickening and
ducing the risk of chronic rejection and late graft failure. duplication of glomerular basement membrane, with
scarring and adhesion [2]. These lesions are also called
transplant glomerulopathy. There are diffuse interstitialOne of the main problems with renal transplantation is
lymphocytic infiltration and various degrees of intersti-represented by a progressive decline in allograft function
tial fibrosis and tubular atrophy. The peritubular capillar-that develops months or years after transplantation and
ies may show thickening and multilayering of the base-is not caused by acute rejection, recurrence of the original
ment membrane which appear to be specific for CR [3].disease, surgical complications or other identifiable fac-
The Banff classification proposed to score CR on thetors. This complication has been called chronic rejection
basis of interstitial fibrosis and tubular atrophy [4], but(CR), as it was thought to be sustained by a continuous
these lesions may be the end result of multiple types ofimmunologic aggression of the host against the allograft.
More recently, the term chronic allograft nephropathy injury, so that it seems to be more appropriate to reserve
(CAN) has been proposed because it was suggested that the term CR to the cases with the characteristic vascular
both alloantigen-dependent and alloantigen-independent changes and/or glomerular abnormalities [5, 6].
mechanisms may participate in the development of this
progressive renal graft dysfunction, eventually leading to
similar histologic features and clinical picture. Although CLINICAL MANIFESTATIONS OF CR
nonimmunological mechanisms may actually play an im- Clinically, CR is characterized by a progressive deteri-
portant role in the pathogenesis of progressive graft fail- oration of kidney allograft function. While some investi-
ure, the term chronic rejection is still appropriate for gators found a regular decline in the creatinine clearance
most cases, both to outline the predominant importance
[7], others reported a large variability in the rate ofof immunologic mechanisms, even in events triggered
progression [8].by alloantigen-independent factors, and to avoid any
Proteinuria and hypertension are often associated withconfusion with the chronic nephropathy caused by the
CR. The onset of proteinuria is generally considered ascalcineurin inhibitors, cyclosporine and tacrolimus.
highly suspicious for an underlying CR. Usually protein-
uria ranges between 1 and 2 g per day [9], but it may be in
PATHOLOGY OF CHRONIC REJECTION a nephrotic range in the case of an underlying transplant
Histologically, CR is characterized by fibrous intimal glomerulopathy [10]. A correlation between the level
thickening of arteriolar and arterial vessels, usually asso- of proteinuria and CR has been found [11]. Arterial
hypertension is extremely common in CR. An associa-
tion between the severity of hypertension and the degreeKey words: transplantation, allograft function, nephropathy, pathogen-
esis, rejection. of histologic [12] or functional [7] damage of grafts with
CR has been reported.Ó 2000 by the International Society of Nephrology
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RISK FACTORS FOR CR later [30, 31]. Recurrent rejections are more often associ-
ated with the development of CR than single episodesFor many years, CR has been considered to be an
of acute rejection [32, 33]. Completely reversible rejec-immune-mediated form of allograft dysfunction generated
tions do not affect the long-term graft survival [34]. Onand perpetuated by alloantigen-dependent mechanisms.
the other hand, studies with protocol biopsies showedMore recently, it has been pointed out that alloantigen-
that even mild increases in plasma creatinine may be asso-independent mechanisms also may cause or accelerate
ciated with histologic signs of acute rejection [17, 35].a chronic allograft nephropathy [13–15]. Alloantigen-
Thus, it is possible that a number of CRs may derivedependent and -independent mechanisms are often in-
from untreated subclinical rejections.tertwined, and it may be difficult to separate the relative
Poor compliance with immunosuppressive therapyimpact of immunologic or nonimmunologic factors on
represents a frequent cause of late graft failure [36, 37]the development and progression of CR. It is our impres-
and a cogent argument supporting the immunologic na-sion, however, that immunologic mechanisms predomi-
ture of CR. The use of too low doses of cyclosporinenate in the pathogenesis of CR.
[38, 39] or a high coefficient of variation of blood cyclos-
porine levels [40] can also expose to an increased risk
IMMUNOLOGICAL FACTORS of CR, again reinforcing the hypothesis that poorly con-
trolled immunologic mechanisms play a predominantClinical data
role in the pathogenesis of CR.One of the strongest arguments in favor of the immu-
nologic origin of CR is represented by the fact that in Experimental data
the long term, the best results are observed with human
Recent studies have shown that antibodies alone orleukocyte antigen (HLA)-identical sibling donors [16].
with the cooperation of T cells can cause CR. ChronicallyMoreover, protocol biopsies at 2 years did not discover
rejecting kidney transplants contain large numbers of
any sign of CR in the recipients of HLA-identical donors
antibody-secreting plasma cells [41], and in aortic allo-
[17]. Even in cadaveric donors, there is a stepwise de-
grafts with CR, an up-regulation of immunoglobulin J,
crease in graft half-life as the number of HLA mis- specific for lymphocytes, has been found [42]. Rats with
matches increase [18, 19]. A possible explanation is that kidney graft and CR produce antibodies against mesan-
HLA incompatibility triggers a continuous, subclinical gial cell, basement membranes and adhesion plaques [43].
host aggression against the allograft, eventually resulting Costimulation may also have an important role in the
in its progressive failure. Clinical studies showed an im- pathogenesis of CR. Early blockade of costimulation
portant role of the indirect pathway of allorecognition with the recombinant fusion protein CTLA4-Ig may pre-
in the pathogenesis of CR. Cells from 82% of renal trans- vent development of CR [44]. Administration of the
plant patients with at least one mismatch for locus HLA- same monoclonal antibody in experimental kidney grafts
DR peptides showed proliferative response to these pep- after the onset of proteinuria prevented deterioration of
tides in vitro, versus only 6% of cells from nonmismatched renal function, showing a role of ongoing T cell activation
controls [20]. The risk of transplant vasculopathy was for progression of CR [45].
significantly higher in patients with persistent T cell pro- Anti-tissue antibodies can contribute to the progres-
liferative responses to donor allopeptides [21]. sion of CR. Anti-decorin and anti-biglycan antibodies
Previous allosensitization affects long-term outcome. might favor the production of transforming growth fac-
The high number of preformed humoral anti-HLA anti- tor-b (TGF-b) by disregulating its activity. In fact, de-
bodies not only exposes the recipient to an increased corin and biglycan serve as extracellular storage site for
risk of acute rejection [22], but is also associated with a TGF-b. Neutralization of these molecules by specific
decline in half-life in both well-matched and mismatched antibodies leaves more TGF-b available for interaction
recipients [18, 23]. Also, the development of anti-HLA with its receptor. This may result in glomerulosclerosis
antibodies after renal transplantation correlates with an and fibrosis [46].
increased risk of CR and graft loss [24]. It appears from these data that antibodies have a cru-
CR has been reported to be a consequence of subopti- cial role in the pathogenesis of CR. It has been hypothe-
mal immunosuppression in the early months following sized that antibodies to cryptic epitopes result in chronic
transplantation [25]. A number of studies reported that damage, whereas antibodies to some of the molecules
CR is more frequent and the half-life of kidney allografts involved in the tissue repair result in change of the tissue
is shorter in patients who developed acute rejection than repair and ultimately in excessive fibrosis [47]. The en-
in patients who never had acute rejection [26–29]. How- hancing role of mediators such as growth factors, cyto-
ever, not all episodes of acute rejection have the same kines, metabolic products, and oxidative stress is well es-
prognostic significance. Early rejections have been found tablished [48]. In this regard, the different expression of
pro-oxidant or antioxidant genes as well as pro-apoptoticto be less predictive of CR than rejections that occur
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or anti-apoptotic genes may be crucial for the develop- rosis [69]. However, more recent reports rather pointed
out the role of programmed senescence, accelerated byment or prevention of CR [49].
Cytomegalovirus (CMV) infection may expose heart immune-mediated and nonimmune injuries leading to
progressive loss of energy generation and to membranetransplant recipients to an increased risk of rejection
[50]. This effect seems to be mediated by immunologic damage [70]. On the other hand, with progression in
transplant care, the impact of older age has been consid-factors as well. Experimental studies showed that CMV
infection may enhance neointima formation of allografts erably attenuated. It has been estimated that the risk of
graft failure using between 1994 and 1997 the kidney ofonly when HLA incompatibility between donor and re-
cipient is present. CMV may increase perivascular influx a donor aged 75 years was comparable to the risk in the
years 1983–1990 by using a donor aged 30 years [71].of monocyte-macrophages early after transplantation
and may up-regulate platelet-derived growth factor, Once again, it seems that the better control of alloanti-
gen-dependent immune reactions through more selectiveTGF-b1, intercellular adhesion molecule-1, and leuko-
cyte function associated molecule-1 [51, 52]. Whether and powerful immunosuppression has a predominant im-
portance over the other risk-factors. The importance ofCMV may cause CR also in renal transplant patients is
still unproven. immunologic factors is also validated by studies showing
excellent long-term results obtained with the use of older
HLA-related living donors [72, 73].
NONIMMUNOLOGICAL FACTORS
The hypothesis that an insufficient number of neph-
A number of studies reported that initial poor graft rons may expose the remnant glomeruli to glomerular
function increases the risk of graft loss in the long term hypertension and hyperfiltration, with eventual develop-
[32, 53–55]. However, the results of other studies [29, 30, ment of focal glomerulosclerosis, led to investigations
33, 56] did not find any influence of delayed graft function into whether a size mismatch between the donor and
on the long-term graft survival. It is difficult to imagine the recipient could play a role in the development of
that acute tubular necrosis (ATN), per se, leads to chronic late graft dysfunction. In some series, the disproportion
renal failure, as it is a common experience that nontrans- between donor and recipient size had a small but signifi-
planted patients who survived to ATN generally main- cant effect on graft survival [74], but other researchers
tain stable renal function over time. Moreover, ischemic did not find any effect of size mismatch on graft survival
injury does not produce chronic lesions in syngeneic [75, 76]. In support of the role of inadequate nephron
grafts [14]. It is possible, however, that ischemic/perfu- dosing, Terasaki et al. [77] reported that kidneys from
sion injury may increase tissue levels of pro-inflammatory women do not survive as long as kidneys from men. On
mediators, including cytokines and adhesion molecules the other hand, the same investigators found that in
and may up-regulate incompatible transplantation anti- transplants between spouses, the results were even better
gens so favoring the onset of acute rejection [57, 58], when the donor was the wife than when the donor was
which, together with the release of free radicals caused the husband [16]. It was hypothesized that this difference
by reperfusion, may eventually lead to intima thickening. may be accounted for by a possible undetectable immune
Recent studies found that delayed graft function can factor in the women. These data also suggest that im-
initiate acute rejection in renal transplant patients [46], mune factors are prevalent on the nonimmune factors.
and it predicts poor long-term graft survival only when Even the explanation that the potential progression of
associated with acute rejection [59–64]. Thus, the long- renal failure might be caused by glomerular hypertension
term consequences of ischemic/reperfusion injury seem and hyperfiltration, eventually leading to focal glomeru-
to be largely mediated by the triggering of immunologic losclerosis, is not completely convincing. In animals, glo-
mechanisms. merular capillary pressure increases following unilateral
The age of the donor may also influence the results nephrectomy only in some strains [78]. The development
of transplantation. The inferior results found with very of progressive renal dysfunction after reduction of neph-
young donors may be accounted for by technical prob- ron mass has considerable variation, being under genetic
lems with relatively small arteries [65]. There is more control [79]. Finally, in CR there is a glomerular ischemia
controversy about the results with older donors. It is rather than a glomerular hyperfiltration, and the histo-
well known that in the elderly, there is a reduction of logic lesions of focal and segmental glomerulosclerosis
glomerular filtration rate as well as a progressive increase are quite rare [12].
of glomerular sclerosis, atherosclerotic lesions, and inter- It has been claimed that the better results observed
stitial fibrosis, although some older kidneys may have with unrelated living donors compared with well-matched
normal function [66]. It has been speculated that the cadaveric donors could be attributed to the fact the living
inferior long-term graft survival observed with the use donors were uniformly healthy without reduction of neph-
of older donors [67, 68] may be attributed to the reduced ron mass caused by ischemia, preexisting diseases, and
delayed graft function [16]. This is certainly a valid expla-renal mass, leading to hyperfiltration and glomeruloscle-
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nation, but again, the most important role is probably of late graft loss [30]. It has also been reported that
hyperlipidemia and oxidative stress are more frequentplayed by immunologic factors. Immune activation can
be initiated not only by the recognition of specific antigen in patients with chronic transplant nephropathy [91], sug-
gesting that oxidized low-density lipoproteins could stim-but also by the recognition of non specific injury. The
latter initiates inflammation, by recruiting lymphocytes, ulate the smooth muscle cell replication and migration.
Once again, however, it is not clear whether hyperlipid-macrophages and dendritic cells; triggers the production
of costimulatory molecules that stimulate T cells; and emia represents the cause or the consequence of a CR
in many cases. On the other hand, the role of lipids maystimulates dendritic traffic into the allograft [59]. More-
over, experimental studies showed that brain death up- be questioned also because in familial hyperlipopro-
teinemia progressive renal disease develops only excep-regulates various lymphocyte- and macrophage-derived
cytokines on somatic organs, thus increasing the immuno- tionally. Other cases of renal diseases associated with
lipid disorders such as lipoprotein glomerulopathy [92]genicity of solid organs [80]. A recent study found an
overexpression of endothelial E-selectin, proximal tubu- or lecithin-cholesterol acyltransferase deficiency [93]
have clinical and histologic patterns completely differentlar HLA-DR antigens, and intercellular and vascular
cell adhesion on molecule-1 in cadaver kidneys, whereas from those of CR.
The presence of proteinuria at 1 year after transplanta-these markers were markedly reduced in living donor
kidneys [58]. The expression of tubular antigens was tion is strongly correlated with CR [9, 10, 12, 83]. It is
however, considered a marker of poor prognosis in thesignificantly associated with acute rejection. Whatever
mechanism is responsible (ischemic changes or immune long term rather than a cause for chronic graft dysfunction.
response), injury self-propagates by inducing a new in-
jury response, which promotes more immune recogni-
THE IMPACT OF
tion, and so on. This might eventually lead to CR [81].
IMMUNOSUPPRESSIVE THERAPY
Theoretically, arterial hypertension could cause chronic
If CR is mainly mediated by immunologic factors, thekidney graft dysfunction. Sustained hypertension can
type of immunosuppression should have a strong impactoverwhelm the autoregulation capacity of the afferent
on the long-term results of renal transplantation. Manypreglomerular arterioles and cause glomerular stretching
investigators think that immunosuppression cannot helpand tension. These changes stimulate the localized pro-
in preventing chronic rejection. This feeling is mainlyduction of angiotensin II, which in turn up-regulates
based on the old data of the United Network for OrganTGF-b1, a fibrogenic growth factor that can cause inter-
Sharing (UNOS) [94] showing that, despite a dramaticstitial fibrosis. Moreover, TGF-b1 may stimulate renin
reduction in the incidence of acute rejection after theproduction, initiating a vicious circle [82, 83]. If this hy-
introduction of cyclosporine, the cadaveric graft half-lifepothesis is correct, one should expect to find a strong
remained pretty unchanged in the period 1975–1979 (7.3correlation between ACE (insertion/deletion) polymor-
years) when cyclosporine was not available, and in thephism and CR. In fact, the D-allele is associated with
period 1985–1990 (7.8 years), when almost all transplantincreased levels of angiotensin converting enzyme
centers were using cyclosporine. This lack of improve-(ACE) and with enhanced conversion of angiotensin I
ment in the long-term graft survival could be attributableto angiotensin II. However, two clinical studies did not
either to the inability of cyclosporine in preventing thecompletely confirm this assumption. One study failed to
immunologic mechanisms of CR or to the nephrotoxicityshow an association between recipient or donor ACE
of cyclosporine which would be responsible of a chronic(I/D) genotype and graft survival [84]. Another study
nephropathy leading to allograft failure. It should beindicated that the effect of ACE (I/D) genotype on graft
pointed out, however, that the two periods consideredsurvival only becomes apparent when other high risk
were very different, which can interfere with the resultsfactors for graft loss are present [85]. There is evidence
of transplantation independently of the type of immuno-that hypertension may have a deleterious effect on long-
suppression. Between 1975 and 1979 there were only fewterm graft survival [86–88]. In many cases, however, hy-
transplant centers, and most of them had great expertise.pertension represents the consequence of a poor graft
In contrast, during recent years many new centers initi-function caused by an already established CR. There-
ated transplant activity. This may have influenced thefore, the role of hypertension as a primary risk factor
results, as the transplant center effect remains the mostfor CR is uncertain.
important variable influencing the results of transplanta-The high prevalence of lipid abnormalities in renal
tion after HLA-identity between donor and recipienttransplant recipients and the histologic similarities be-
[95]. Moreover, while in the past most transplant recipi-tween arteriosclerosis and CR have suggested a role for
ents were young, without comorbidity and received thehyperlipidemia in the pathogenesis of chronic allograft
kidney of young donors, in the last few years older pa-dysfunction [89, 90]. In multivariate analysis, hypertri-
glyceridemia was found to be an independent risk factor tients, diabetics, patients with cardiovascular disease or
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systemic diseases have been accepted for transplantation and the new microemulsion of cyclosporine [109, 110]
proved to be able to reduce the rate of acute rejectionand this certainly affected the patient and the graft sur-
vival. There is also an increasing use of marginal kidneys, when compared to regimens based on the old formula-
tion of cyclosporine. Also, the addition to cyclosporinewhich may have shorter graft survival than optimal kid-
neys. Therefore, the two periods considered are hardly of mycophenolate mofetil [111], basiliximab [112, 113],
daclizumab [114, 115], could significantly reduce thecomparable.
In spite of these biases, the most recent data of UNOS number of acute rejections. The follow-ups of these stud-
ies are too short to evaluate whether this protective effectreported an increase in cadaveric graft half-life to 10.4
years, for renal transplants performed between 1995 and on acute rejection may also have a favorable impact on
CR. However, a recent analysis at 3 years post-trans-1996 [96]. On the other hand a number of studies showed
that cyclosporine may allow excellent results in the long plantation reported that there was a 7.6% reduction of
graft loss in patients who added mycophenolate mofetilterm, superior to those obtained with azathioprine plus
steroids. Two controlled trials showed that the 10-year to cyclosporine and steroids when compared with those
who added azathioprine or placebo [116]. A retrospec-cadaveric renal transplant survival was significantly bet-
ter in patients assigned to receive cyclosporine than in tive analysis of the UNOS data reported that tacrolimus
improved long-term renal allograft survival and reducedthose assigned to azathioprine [97, 98]. In our own cumu-
lative experience with cyclosporine, the graft half-life the rate of graft loss from CR [117]. However, there was
a huge difference between the small number of patientswas 19.9 years and the pure graft half-life, excluding
death, was 24.8 years [32]. In an Italian collaborative given tacrolimus and the large number of patients given
cyclosporine. Moreover, only selected centers used ta-trial involving 12 centers, three different modalities of
administration of cyclosporine in cadaveric renal trans- crolimus while cyclosporine was adopted by most cen-
ters. These biases may limit the importance of this retro-plant recipients were compared [99]. The mean graft
half-lives were, respectively, 16.4 years for monotherapy, spective analysis. It has also been postulated that
12.6 for double therapy, 19.0 for triple therapy. In Bel- tacrolimus might be less nephrotoxic than cyclosporine,
gium, Vanrenterghem [100] reported a graft half-life of as cyclosporine overexpresses TGF-b1 in stimulated hu-
21.8 years in cyclosporine-treated renal transplant recipi- man T cells [118] while tacrolimus would produce a lower
ents younger than 50 years. By reviewing the data of stimulation of TGF-b1 [119] a powerful stimulator of
Collaborative Transplant Study, Opelz [101] reported a fibrogenesis. However, TGF-b quantitation can be tricky.
half-life of more than 17 years for first cadaver grafts The measurement may be limited by the analytical tech-
initially treated with cyclosporine, azathioprine and ste- nique used or by the possibility of artifacts. As a matter of
roids. In summary, both uncontrolled and controlled fact, a recent paper reported that in liver transplantation
studies showed that a cyclosporine-based immunosup- neither cyclosporine nor tacrolimus induced active
pression can obtain a cadaveric graft survival quite longer TGF-b1 blood levels [120]. On the other hand, TGF-b is
than that reported by the old UNOS data. These data a pluripotent cytokine with important anti-inflammatory
further demonstrate how important is the control of the and immunosuppressive effects [121], which could theo-
immune response to prevent late graft failure. retically protect the allograft from immunologic aggres-
There is no doubt that cyclosporine is a nephrotoxic sion. Only long-term, randomized well-designed trials
agent, but when appropriately handled, its deleterious would ascertain whether one drug is superior to the other
effect on long-term graft function may be avoided. Sev- in protecting from chronic allograft dysfunction.
eral studies in cyclosporine-treated renal transplant re-
cipients showed no attrition of graft function in the long
CONCLUSIONSterm [102–104]. Other studies reported that after the
Many clinical and experimental data support the hy-first year the decline in creatinine clearance is parallel
pothesis that CR is mainly sustained by immunologicbetween patients given cyclosporine and azathioprine
factors. Even those mechanisms which are initially allo-[105], suggesting that factors other than cyclosporine
antigen-independent seem to damage the kidney allo-nephrotoxicity influenced the long-term allograft out-
graft through the mediation of immunologic factors. Thiscome. We recently evaluated the mean values of creati-
does not mean that alloantigen-independent factorsnine clearance in a cohort of cyclosporine-treated pa-
should be neglected, as they can actually produce kidneytients with kidney allograft functioning for 10 years. With
damage and may also exert harmful extra-renal effects.the exception of a subgroup of patients with the lowest
However, given the predominance of the role of immu-mean creatinine clearance at 1 year, no significant decline
nologic mechanisms, every effort should be made to re-in graft function was seen, showing that cyclosporine
duce the impact of alloantigen-dependent factors in trig-does not necessarily produce renal function attrition in
gering and sustaining CR. In this regard, good HLAthe long term [106].
Randomized trials showed that tacrolimus [107, 108], compatibility, good compliance of the recipient, prefer-
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14. Paul LC: Chronic allograft nephropathy. Kidney Int 56:783–793,term. We are convinced, however, that the most impor-
1999
tant variable in influencing the long-term results is repre- 15. Ponticelli C: Chronic kidney allograft dysfunction in the
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